Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.33 |
| ▸ | LOX | P28300 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.30 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5326251 | 0.93 | LOXL2 (0.37) | LOXL2LOXCYP2D6KCNH2MAOA | |
| SCHEMBL12338687 | 0.71 | — | — | |
| SCHEMBL5951485 | 0.70 | LOXL2 (0.35) | LOXL2LOXNR3C2 | |
| SCHEMBL2993441 | 0.70 | SKP2 (0.44) | — | |
| SCHEMBL11390001 | 0.68 | SIGMAR1 (0.47) | NR3C2 | |
| SCHEMBL1146845 | 0.68 | SKP2 (0.43) | — | |
| SCHEMBL29191290 | 0.68 | SKP2 (0.40) | — | |
| SCHEMBL1446914 | 0.67 | TDP1 (0.46) | — | |
| SCHEMBL7964430 | 0.67 | TDP1 (0.46) | — | |
| SCHEMBL7963811 | 0.67 | TDP1 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11766478-B2 | Methods for enhancing antigen-specific immune responses | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-09-26 | — | — | US | disclosed |
| US-20200390885-A1 | METHODS FOR ENHANCING ANTIGEN-SPECIFIC IMMUNE RESPONSES | THE JOHNS HOPKINS UNIVERSITY | 2020-12-17 | — | — | US | disclosed |
| US-10799579-B2 | Methods for enhancing antigen-specific immune responses | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-10-13 | — | — | US | disclosed |
| US-20180169221-A1 | Methods for Enhancing Antigen-Specific Immune Responses | THE JOHNS HOPKINS UNIVERSITY | 2018-06-21 | — | — | US | disclosed |
| WO-2016191641-A2 | METHODS FOR ENHANCING ANTIGEN-SPECIFIC IMMUNE RESPONSES USING COMBINATION THERAPY COMPRISING PAPILLOMAVIRUS CAPSID ANTIGENS | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-12-01 | — | — | WO | disclosed |
| WO-2016115431-A1 | METHODS FOR ENHANCING ANTIGEN-SPECIFIC IMMUNE RESPONSES | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-07-21 | — | — | WO | disclosed |
| WO-2016025295-A1 | COMPOSITIONS AND METHODS FOR ENHANCING ANTIGEN-SPECIFIC IMMUNE RESPONSES | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-02-18 | — | — | WO | disclosed |
| US-9085638-B2 | DNA vaccine enhancement with MHC class II activators | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-07-21 | — | — | US | disclosed |
| US-20150182621-A1 | COMPOSITIONS AND METHODS FOR ENHANCING ANTIGEN-SPECIFIC IMMUNE RESPONSES | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2015-07-02 | — | — | US | disclosed |
| US-20120244173-A1 | Compositions and Methods for Enhancing Antigen-Specific Immune Responses | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2012-09-27 | — | — | US | disclosed |
| US-20120225090-A1 | METHODS FOR ENHANCING ANTIGEN-SPECIFIC IMMUNE RESPONSES | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-09-06 | — | — | US | disclosed |
| EP-2424990-A2 | COMPOSITIONS AND METHODS FOR ENHANCING ANTIGEN-SPECIFIC IMMUNE RESPONSES | The Johns Hopkins University (US) | 2012-03-07 | — | — | EP | disclosed |
| WO-2011017162-A2 | METHODS FOR ENHANCING ANTIGEN-SPECIFIC IMMUNE RESPONSES | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-02-10 | — | — | WO | disclosed |
| US-20100330105-A1 | Anticancer Combination Therapies | JOHN HOPKINS UNIVERSITY (US) | 2010-12-30 | — | — | US | disclosed |
| WO-2010129339-A2 | COMPOSITIONS AND METHODS FOR ENHANCING ANTIGEN-SPECIFIC IMMUNE RESPONSES | THE JOHNS HOPKINS UNIVERSITY (US) | 2010-11-11 | — | — | WO | disclosed |
| US-20090093050-A1 | DNA Vaccine Enhancement with MHC Class II Activators | THE JOHNS HOPKINS UNIVERSITY | 2009-04-09 | — | — | US | disclosed |
| WO-2008024844-A2 | ANTICANCER COMBINATION THERAPIES | THE JOHNS HOPKINS UNIVERSITY (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120244173-A1 | Compositions and Methods for Enhancing Antigen-Specific Immune Responses | PCNA, MYC, MCTS1 | LOXL2 2328/4885LOX 2400/4885CYP2D6 4812/4885 |
| US-20120225090-A1 | METHODS FOR ENHANCING ANTIGEN-SPECIFIC IMMUNE RESPONSES | LY96, STING1, CD69 | LOXL2 3346/4885LOX 2971/4885CYP2D6 4792/4885 |
| US-20090093050-A1 | DNA Vaccine Enhancement with MHC Class II Activators | HLA-DRB1, MICA, CD74 | LOXL2 3820/4885LOX 4516/4885CYP2D6 4356/4885 |
| US-20100330105-A1 | Anticancer Combination Therapies | TP53, TOP2B, TOP2A | LOXL2 3706/4885LOX 3463/4885CYP2D6 4633/4885 |
| US-20150182621-A1 | COMPOSITIONS AND METHODS FOR ENHANCING ANTIGEN-SPECIFIC IMMUNE RESPONSES | MYC, TP53, MKI67 | LOXL2 3176/4885LOX 2768/4885CYP2D6 4868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.